Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

INOVIO PHA Form 4 May 15, 2017	ARMACEUTICA	LS, INC.										
FORM 4 Check this box if no longer subject to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF									APPROVAL 3235-0287 January 31, 2005 A average			
Section 10 Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	Filed purs Section 17(a) of the P		ility Hol	ne Idi	Securition ng Com	pany	Act of	e Act of 1934, f 1935 or Section 40	burden hou response	•	
(Print or Type R	esponses)											
DHILLON AVTAR S Symi INO			2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [INO]					-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
L.				of Earliest Transaction Day/Year)					X_ Director 10% Owner Officer (give title Other (specify below) below)			
				endment, Date Original onth/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)		Zip)	Table	I - Non-l	De	rivative S	ecurit	ies Acc	juired, Disposed of	f. or Beneficial	lv Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ned 1 Date, if	3.	ior)		ies Ac sposed	quired of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common Stock	05/13/2017			M		10,000	A	<u>(1)</u>	73,333	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if TransactionDerivative any Code Securitie (Month/Day/Year) (Instr. 8) (A) or Discussion (D)		Securities (A) or Dis	Acquired posed of	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Ar Underlying Se (Instr. 3 and 4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Restricted Stock Unit	(2)	05/12/2017		А	7,669		(2)	(2)	Common Stock
Common Stock Options	\$ 7.14	05/12/2017		А	12,500		05/12/2018 <u>(3)</u>	05/12/2027	Common Stock
Restricted Stock Unit	<u>(1)</u>	05/13/2017		М		10,000	(1)	(1)	Common Stock

Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

Reporting Owners

Reporting Person

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
DHILLON AVTAR S 660 W. GERMANTOWN F PLYMOUTH MEETING, F	Х						
Signatures							
Avtar S. Dhillon	05/15/2017						
**Signature of	Date						

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on (1) May 13, 2017.
- Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% (2)on May 12, 2018.
- (3) Options to vest 100% on May 12, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.